NCT04914611

Real World Assessment of People Living With Chronic Hepatitis B in Australia

Name: Clinical Trial NCT04914611
Creator: Kirby Institute
Keywords: Hepatitis B, No intervention, other, clinical trial, Australia

Kirby Institute·ClinicalTrials.gov·otherRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Hepatitis B
Drug/Device/Intervention: No intervention
Study type: Observational
Intervention type: other

Sponsor & location

Primary sponsor: Kirby Institute
Location: Sydney, Australia

Timeline & enrollment

Phase: N/A
Start date: Feb 17, 2022
End date: Jul 01, 2027
Enrollment: 10000 participants

Primary outcome

Characterisation of HBV

Summary

The REACH-B study establishes an observational cohort study of people living with chronic hepatitis B from a national network, including a diverse range of services, to characterise and monitor hepatitis B linkage to care and treatment requirements amongst this population.

ICD-10 classifications

Acute hepatitis BAcute hepatitis B without delta-agent and without hepatic comaAcute delta-(super)infection in chronic hepatitis BChronic viral hepatitis B without delta-agentChronic viral hepatitis B without delta-agent : other and unspecified phase

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT04914611
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT04914611 through Pure Global AI's free database. This phase not specified trial is sponsored by Kirby Institute and is currently Recruiting. The study focuses on Hepatitis B. Target enrollment is 10000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.